Abstract:Glioblastoma (GBM) is the highest grade of glioma for which no effective therapy is currently available. Despite extensive research in diagnosis and therapy, there has been no significant improvement in GBM outcomes, with a median overall survival continuing at a dismal 15–18 months. In recent times, glioblastoma stem cells (GSCs) have been identified as crucial drivers of treatment resistance and tumor recurrence, and GBM therapies targeting GSCs are expected to improve patient outcomes. We used a multistep in silico screening strategy to identify repurposed candidate drugs against selected therapeutic molecular targets in GBM with potential to concomitantly target GSCs. Common differentially expressed genes (DEGs) were identified through analysis of multiple GBM and GSC datasets from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). For identification of target genes, we selected the genes with most significant effect on overall patient survival. The relative mRNA and protein expression of the selected genes in TCGA control versus GBM samples was also validated and their cancer dependency scores were assessed. Drugs targeting these genes and their corresponding proteins were identified from LINCS database using Connectivity Map (CMap) portal and by in silico molecular docking against each individual target using FDA-approved drug library from the DrugBank database, respectively. The molecules thus obtained were further evaluated for their ability to cross blood brain barrier (BBB) and their likelihood of resulting in drug resistance by acting as p-glycoprotein (p-Gp) substrates. The growth inhibitory effect of these final shortlisted compounds was examined on a panel of GBM cell lines and compared with temozolomide through the drug sensitivity EC50 values and AUC from the PRISM Repurposing Secondary Screen, and the IC50 values were obtained from GDSC portal. We identified RPA3, PSMA2, PSMC2, BLVRA, and HUS1 as molecular targets in GBM including GSCs with significant impact on patient survival. Our results show GSK-2126458/omipalisib, linifanib, drospirenone, eltrombopag, nilotinib, and PD198306 as candidate drugs which can be further evaluated for their anti-tumor potential against GBM. Through this work, we identified repurposed candidate therapeutics against GBM utilizing a GSC inclusive targeting approach, which demonstrated high in vitro efficacy and can prospectively evade drug resistance. These drugs have the potential to be developed as individual or combination therapy to improve GBM outcomes.

Dddr-17. A Facile High Throughput Drug Screening Platform Enables The Construction Of A Pharmaco-Proteogenomic Interaction Landscape In Glioblastoma

A Dual Receptor Targeting and Blood–brain Barrier Penetrating Co-Drug-loaded Particle Mediating Inhibition of Oxidative Phosphorylation for Targeted Therapy of Glioblastoma

A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell models

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells

Dddr-05. Spatially Resolved Drug Sensitivity Profiling In Glioblastoma

Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma

Dddr-34. A Systems Medicine Platform For Individualized Treatment Of Glioblastoma

Dddr-33. Transcriptomics-Based Novel Drug Discovery In Diffuse Midline Glioma

Dddr-42. Leveraging Genome-Wide Crispr/Cas9 Knockout Drug Screens To Identify Sensitizers For Proteosome Inhibitors In Glioblastoma

Exth-16. Unbiased Discovery Of Synergistic Vulnerabilities Against Glioblastoma: An Innovativein Vivo Crispr Profiling Platform To Unleash The Power Of Tumor-Targeted Cytokine Therapy

Abstract 3503: New generation drug development from in-silico identification to preclinical evaluation in glioblastoma

Epco-36. Integrative Deep-Learning And Pharmacogenomic Profiling Of Malignant Gliomas Using Patient-Derived Tumor Cells

Stem-18. A High Throughput Neurosphere Based Colony Formation Assay To Validate Drug And Radiation Effectiveness In Patient Derived Xenolines

Rapid Processing and Drug Evaluation in Glioblastoma Patient-Derived Organoid Models with 4D Bioprinted Arrays

Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening

High-throughput glycolytic inhibitor discovery targeting glioblastoma by graphite dots–assisted LDI mass spectrometry

Integrated Mapping of Pharmacokinetics and Pharmacodynamics in a Patient-Derived Xenograft Model of Glioblastoma.

DIPG-34. IDENTIFICATION OF CAR-T CELL ENHANCING COMPOUNDS USING HIGH THROUGHPUT SCREENING

Abstract A015: Predicting efficacious drugs and drug-biomarker relationships for targeted glioblastoma treatment